NASDAQ:CRSP - Crispr Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$58.35 -0.04 (-0.07 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$58.35
Today's Range$57.38 - $60.00
52-Week Range$16.16 - $73.90
Volume687,316 shs
Average Volume892,637 shs
Market Capitalization$2.76 billion
P/E Ratio-34.12
Dividend YieldN/A
Crispr Therapeutics logoCRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio24.42
Quick Ratio24.42


Trailing P/E Ratio-34.12
Forward P/E Ratio-22.44
P/E GrowthN/A

Sales & Book Value

Annual Sales$41 million
Price / Sales67.16
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book14.27


EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-189.60%
Return on Equity-35.18%
Return on Assets-24.39%


Outstanding Shares47,190,000
Market Cap$2,755.24

Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

What is Crispr Therapeutics' stock symbol?

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How were Crispr Therapeutics' earnings last quarter?

Crispr Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. The company had revenue of $1.36 million for the quarter, compared to analyst estimates of $3.64 million. Crispr Therapeutics had a negative return on equity of 35.18% and a negative net margin of 189.60%. The firm's revenue was down 49.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.54) earnings per share. View Crispr Therapeutics' Earnings History.

When is Crispr Therapeutics' next earnings date?

Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Crispr Therapeutics.

What price target have analysts set for CRSP?

9 equities research analysts have issued twelve-month price objectives for Crispr Therapeutics' shares. Their forecasts range from $51.00 to $86.00. On average, they expect Crispr Therapeutics' share price to reach $65.1714 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Ratings for Crispr Therapeutics.

What is the consensus analysts' recommendation for Crispr Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Crispr Therapeutics stock?

Here are some recent quotes from research analysts about Crispr Therapeutics stock:
  • 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (7/10/2018)
  • 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
  • 3. Chardan Capital analysts commented, "We calculated the CRISPR sector enterprise value (EV) by discounting Chardan target sector EVs of companies in the AAV (assumed 3 years ahead) and small RNA (assumed 3 years ahead) gene therapy sectors; we applied a discount rate of 20%, which we believe is reasonable for preclinical biotech firms. Giving CRSP a CRISPR sector valuation distribution of 15% of the calculated CRISPR sector EV (based on our view of the firm’s relative IP weakness balanced by potential first entry of a CRISPR therapy into the clinic) and adding $272.3 mm in cash, we project a CRSP market cap range of $866 mm-$901 mm." (8/14/2017)

Who are some of Crispr Therapeutics' key competitors?

Who are Crispr Therapeutics' key executives?

Crispr Therapeutics' management team includes the folowing people:
  • Dr. Rodger Novak, Founder & Chairman (Age 51)
  • Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
  • Dr. N. Anthony Coles Jr., Sr. Advisor (Age 58)
  • Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)
  • Dr. Chad Cowan, Scientific Founder

When did Crispr Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Has Crispr Therapeutics been receiving favorable news coverage?

Headlines about CRSP stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Crispr Therapeutics earned a news sentiment score of 0.04 on Accern's scale. They also gave news articles about the company an impact score of 46.93 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Crispr Therapeutics' major shareholders?

Crispr Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (7.65%), Bank of Montreal Can (0.20%), Essex Investment Management Co. LLC (0.09%), Fox Run Management L.L.C. (0.02%) and Fred Alger Management Inc. (0.01%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Simeon George, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Institutional Ownership Trends for Crispr Therapeutics.

Which institutional investors are selling Crispr Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Insider Buying and Selling for Crispr Therapeutics.

Which institutional investors are buying Crispr Therapeutics stock?

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Essex Investment Management Co. LLC, Fox Run Management L.L.C. and Fred Alger Management Inc.. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer, Corp /De/ Celgene and Simeon George. View Insider Buying and Selling for Crispr Therapeutics.

How do I buy shares of Crispr Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Crispr Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $58.35.

How big of a company is Crispr Therapeutics?

Crispr Therapeutics has a market capitalization of $2.76 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Crispr Therapeutics employs 127 workers across the globe.

How can I contact Crispr Therapeutics?

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.

MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.